Under construction – not a live service
Sign in
Taking people in ChinaNo phase

AI decision support for clot-dissolving treatment in acute ischemic stroke

Tests an AI tool to guide clot-dissolving treatment in adults with acute stroke.

Plain-language title generated from the registry record
Registry title: Artificial Intelligence Support for Stroke

Key facts

Where
Changsha, ChinaSee the site

Where in China

  • Liuyang Jili HospitalChangsha, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Capital Medical University
Trial code
NCT07785492
Record updated
27 August 2026
Original description
This study investigates whether an AI-assisted decision support tool, compared with standard care, increases the proportion of acute ischemic stroke patients receiving intravenous thrombolysis within 24 hours of symptom onset at a primary hospital in China, while also evaluating its impact on clinical outcomes, treatment timelines, and safety.Read full original descriptionShow less

Artificial Intelligence-Assisted Decision Support for Intravenous Thrombolysis in Acute Ischemic Stroke at Basic Hospitals in China (ASSIST)

This study investigates whether an AI-assisted decision support tool, compared with standard care, increases the proportion of acute ischemic stroke patients receiving intravenous thrombolysis within 24 hours of symptom onset at a primary hospital in China, while also evaluating its impact on clinical outcomes, treatment timelines, and safety.

Inclusion: Age ≥18 years; Clinical diagnosis of acute ischemic stroke; Onset time (last known well) <24 hours; CT or MRI examination excluding intracerebral hemorrhage; Signed informed consent by the patient or a legally authorized representative.

Exclusion: Currently participating in another interventional clinical trial related to drugs or devices; Has received intravenous thrombolysis at another hospital; Has completed a definitive reperfusion therapy decision at another hospital and is transferred to this hospital solely for follow-up observation or rehabilitation; Pregnant women.

ClinicalTrials.gov NCT07785492